About: Treatment of Chronic Hepatitis B in 2002

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of Chronic Hepatitis B in 2002 Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Viral hepatitis B is one of the most serious health problems of recent period, above all in the world?s developing countries. It is estimated that two billion people will be infected with the hepatitis B virus in the course of their lives and between 350 and 400 million people are chronically infected at present. The aims of the treatment of chronic hepatitis B are to achieve sustained suppression of viral replication and remission of liver disease. For the treatment of chronic hepatitis B two drugs have been licensed worldwide: alpha-interferon and lamivudine. The third potent drug, adefovir dipivoxil, is now approved only in the United States. In chronic hepatitis B therapy there are new and exciting developments in antiviral, such as nucleoside analogs - entecavir, emtricitabine, clevudine, beta-L-nucleosides. Studies, comparing pegylated interferon with lamivudine and with combination of lamivudine and pegylated interferon are in progress. Several innovative antiviral approaches have been evaluate Viral hepatitis B is one of the most serious health problems of recent period, above all in the world?s developing countries. It is estimated that two billion people will be infected with the hepatitis B virus in the course of their lives and between 350 and 400 million people are chronically infected at present. The aims of the treatment of chronic hepatitis B are to achieve sustained suppression of viral replication and remission of liver disease. For the treatment of chronic hepatitis B two drugs have been licensed worldwide: alpha-interferon and lamivudine. The third potent drug, adefovir dipivoxil, is now approved only in the United States. In chronic hepatitis B therapy there are new and exciting developments in antiviral, such as nucleoside analogs - entecavir, emtricitabine, clevudine, beta-L-nucleosides. Studies, comparing pegylated interferon with lamivudine and with combination of lamivudine and pegylated interferon are in progress. Several innovative antiviral approaches have been evaluate (en)
Title	Treatment of Chronic Hepatitis B in 2002 Treatment of Chronic Hepatitis B in 2002 (en)
skos:prefLabel	Treatment of Chronic Hepatitis B in 2002 Treatment of Chronic Hepatitis B in 2002 (en)
skos:notation	RIV/65269705:_____/03:00007828!RIV/2004/MZ0/L43004/N
http://linked.open.../vavai/riv/strany	59-63
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(NI7484)
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2004
http://linked.open...aciTvurceVysledku	Husa, Petr Husová, Libuše
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice Brno / (nerozlišená součást)
http://linked.open...dnocenehoVysledku	631449
http://linked.open...ai/riv/idVysledku	RIV/65269705:_____/03:00007828
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	chronic hepatitis B;alpha-interferon;lamivudine;adefovir dipivoxil;nucleoside analogs;pegylated interferon (en)
http://linked.open.../riv/klicoveSlovo	adefovir dipivoxil lamivudine nucleoside analogs pegylated interferon chronic hepatitis B alpha-interferon
http://linked.open...odStatuVydavatele	SK - Slovenská republika
http://linked.open...ontrolniKodProRIV	[6A001F3A43F1]
http://linked.open...i/riv/nazevZdroje	Bratislavské lekárské listy
http://linked.open...in/vavai/riv/obor	FN
http://linked.open...ichTvurcuVysledku	2 (xsd:int)
http://linked.open...cetTvurcuVysledku	2 (xsd:int)
http://linked.open...ocetUcastnikuAkce	0 (xsd:int)
http://linked.open...nichUcastnikuAkce	0 (xsd:int)
http://linked.open...vavai/riv/projekt	Dependence of sustained virological response on the early viral kinetics in the treatment of chronic hepatitis C patients with combination of alpha-interferon, or pegylated interferon, and ribavirin.
http://linked.open...UplatneniVysledku	2003
http://linked.open...v/svazekPeriodika	104
http://linked.open...iv/tvurceVysledku	Husa, Petr Husová, Libuše
issn	0006-9248
number of pages	5 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software